[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345232-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345232-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-blzf1-in-lung-adenocarcinoma-and-its-value-as-a-diagnostic-and-prognostic-biomarker","The role of BLZF1 in lung adenocarcinoma and its value as a diagnostic and prognostic biomarker","","Lung adenocarcinoma (LUAD) is the most common lung cancer and remains difficult to diagnose early. This study analyzes BLZF1 expression in 505 LUAD patients from TCGA and 60 LUAD patients from Yunnan Cancer Hospital, comparing tumor tissues with para-cancer tissues. BLZF1 mRNA and protein levels are significantly higher in cancer samples, with strong diagnostic discrimination by ROC analysis. Higher BLZF1 expression correlates with advanced T stage and worse recurrence-free and overall survival. Mechanistic analyses suggest involvement in Golgi function, vesicle transport, and glycolysis-related pathways. siRNA-mediated BLZF1 downregulation suppresses LUAD cell proliferation, cloning, migration, and invasion, supporting BLZF1 as a potential diagnostic and prognostic biomarker.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-blzf1-in-lung-adenocarcinoma-and-its-value-as-a-diagnostic-and-prognostic-biomarker/345232/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-blzf1-in-lung-adenocarcinoma-and-its-value-as-a-diagnostic-and-prognostic-biomarker/345232.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What data sources were used to evaluate BLZF1 in lung adenocarcinoma?","Question",{"text":63,"@type":64},"The study used 505 LUAD patients from the TCGA dataset and 60 LUAD patients from Yunnan Cancer Hospital as a clinical dataset.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does BLZF1 perform as a diagnostic marker in the two datasets?",{"text":68,"@type":64},"ROC curve analysis yielded an AUC of 0.759 in the TCGA dataset and 0.9985 in the clinical dataset, indicating diagnostic discrimination.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the relationship between BLZF1 expression and patient prognosis?",{"text":72,"@type":64},"Higher BLZF1 expression is associated with decreased recurrence-free survival and overall survival, with reported hazard ratios and significant P values in the survival analyses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345232,1790177485,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe role of BLZF1 in lung adenocarcinoma and its value as a diagnostic and prognostic biomarker  \nChen Zhou1,6, Zaoxiu Hu2,6, Tang Yu3,6, Tingdong Yu4, Qiubo Huang1, Jie Zhao1, Mingsheng Ma5, Yunchao Huang1 & Lianhua Ye1,5􀀍  \nLung adenocarcinoma (LUAD) is the most common type of lung cancer and seriously threatens the lives of many people worldwide. The difficulty in early diagnosis of lung cancer has always been a difficulty in lung cancer treatment, and basic leucine zipper nuclear factor 1 (BLZF1) has been shown to promote the occurrence and development of various cancers. This study used 505 LUAD patients in TCGA (TCGA dataset) and 60 LUAD patients in Yunnan Cancer Hospital (Clinical dataset) as research subjects to explore the role of BLZF1 in LUAD. The study found that the expression levels of mRNA and protein of the BLZF1 gene in cancer tissues were significantly higher than those in para-cancer tissues in theTCGA dataset and clinical dataset (P \u003C 0.001) . Receiver operating characteristic (ROC) curves analysis found that theAUC value of BLZF1 was 0.759 (95% CI = 0.7049–0.8140, P \u003C 0.0001) in theTCGA dataset, and theAUC value was 0.9985 (95% CI = 0.9954–1.0000, P \u003C 0.0001) in the clinical dataset. Moreover, the BLZF1 gene expression level in the two data sets was significantly correlated with the patient’sT stage, and survival analysis showed that high BLZF1 gene expression levels were associated with decreased recurrence-free survival (RFS) (HR = 1.510, 95% Cl = 1.095–2.083, P = 0.012) and overall survival (OS) (HR = 1.472, 95% Cl = 1.099–1.973, P = 0.010). Protein-protein interaction (PPI) and enrichment analysis showed that the BLZF1 gene was closely associated with biological processes such as Golgi function, vesicle transport and cell membrane system maintenance. The expression correlation of BLZF1 with glycolysis-related genes indicated that BLZF1 may play a role in LUAD by participating in the sugar metabolism pathway. In addition, this study downregulated the expression of BLZF1 by small interfering RNA (si-BLZF1), and downregulation of BLZF1 expression significantly inhibited the proliferation, cloning, migration and invasion of LUAD cells. Therefore, BLZF1 may be involved in the occurrence and development of lung adenocarcinoma, which can be a potential diagnostic biomarker in clinical practice.  \nKeywords Basic leucine zipper nuclear factor 1, Clinical data, Glycolytic, Lung adenocarcinoma, TCGA dataset  \nLung cancer is the second most common cancer and the leading cause of cancer death worldwide1. The two main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which NSCLC accounts for 85% of lung cancer2. Lung adenocarcinoma (LUAD) is the most common NSCLC, accounting for about 40–50% of the total. Lung cancer is difficult to detect early, has high tumor biological malignancy, complex molecular heterogeneity, the susceptibility to recurrence and metastasis3–5, which have always been  \n1Department of Thoracic Surgery I, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunan, Kunming 650100, China. 2Department of pathology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunan, Kunming 650100, China. 3Yunan Key Laboratory of Breast Cancer Precision Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunan, Kunming 650100, China. 4Department of Hepatobiliary Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunan, Kunming 650100, China.  \n5Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650033, China. 6These authors contributed equally to this","cbCaim0BmrQP7FNN","https://ap.wps.com/l/cbCaim0BmrQP7FNN","pdf",2919659,15,"English","# Background\n## Limitations of current lung cancer biomarkers\n## Rationale for studying BLZF1 in LUAD\n# Study design and datasets\n## TCGA dataset\n## Clinical dataset\n# Results\n## BLZF1 expression in tumor vs. para-cancer tissues\n## Diagnostic performance by ROC\n## Associations with T stage and survival outcomes\n## PPI and enrichment pathway insights\n## Correlation with glycolysis-related genes\n# Functional validation\n## si-BLZF1 effects on LUAD cell behaviors\n# Conclusion and clinical implication","[{\"question\":\"What data sources were used to evaluate BLZF1 in lung adenocarcinoma?\",\"answer\":\"The study used 505 LUAD patients from the TCGA dataset and 60 LUAD patients from Yunnan Cancer Hospital as a clinical dataset.\"},{\"question\":\"How does BLZF1 perform as a diagnostic marker in the two datasets?\",\"answer\":\"ROC curve analysis yielded an AUC of 0.759 in the TCGA dataset and 0.9985 in the clinical dataset, indicating diagnostic discrimination.\"},{\"question\":\"What is the relationship between BLZF1 expression and patient prognosis?\",\"answer\":\"Higher BLZF1 expression is associated with decreased recurrence-free survival and overall survival, with reported hazard ratios and significant P values in the survival analyses.\"}]","The role of BLZF1 in lung adenocarcinoma and its value as a diagnostic and prognostic biomarker | PDF",1790056899,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6f0aaee5d69ee4b93ba3d74847d8ca7.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a303f2288221070e77b9f64bc62d907.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65f29dd18ca84948e6fdb816f42db960.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc939f3a8086ae43f58e7d84c3dbdae6.webp",980,1287]